Tiziana announces publication of a peer-reviewed article on the intranasal administration of foralumab demonstrating modulated effector cd8+ t cell function and an induced t cell regulatory response in human subjects
New york, nov. 23, 2022 (globe newswire) -- tiziana life sciences ltd. (nasdaq: tlsa) (“tiziana” or the “company”), a biotechnology company enabling breakthrough cns immunomodulation approaches to enhance the functionality of treg-based therapies, announces publication of a scientific article in the peer-reviewed journal frontiers in immunology entitled “nasal administration of anti-cd3 monoclonal antibody modulates effector cd8+ t cell function and induces a regulatory response in t cells in human subjects” (1) . the study was completed by researchers at the brigham and womens hospital (bwh) and harvard medical school. the goal of the study was to assess safety and the immune effects of an entirely human, previously uncharacterized nasal anti-cd3 mab (foralumab) in humans and its in vitro stimulatory properties. the findings support tiziana's intranasal foralumab platform as a new modality for the treatment of autoimmune and cns diseases.
TLSA Ratings Summary
TLSA Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission